Literature DB >> 11040245

Angiotensin II stimulates extracellular signal-regulated kinase activity in intact pressurized rat mesenteric resistance arteries.

K Matrougui1, Y E Eskildsen-Helmond, A Fiebeler, D Henrion, B I Levy, A Tedgui, M J Mulvany.   

Abstract

The activation of extracellular signal-regulated kinases 1/2 (ERK1/2) was assessed in isolated rat mesenteric resistance arteries (200-micrometer diameter) in a pressure myograph and stimulated for 5 minutes by angiotensin II (Ang II, 0.1 micromol/L) with a pressure of 70 mm Hg. ERK1/2 activity was measured by using an in-gel assay, and ERK1/2 phosphorylation was measured by Western blot analysis with use of a phospho-specific ERK1/2 antibody. Ang II (0.1 micromol/L) induced contraction (28% of phenylephrine contraction, 10 micromol/L). ERK kinase inhibitor PD98059 (10 micromol/L) attenuated this contraction by 36% but not that to phenylephrine or K(+) (60 mmol/L). In unpressurized arteries, Ang II increased ERK1/2 activity by 26%, and pressure (70 mm Hg) itself increased ERK1/2 activity by 72%. Ang II and pressure together acted synergistically, increasing ERK1/2 activity by 264%. Thus, in pressurized vessels, Ang II (0.1 micromol/L) increased ERK1/2 activity by 112%, calculated as [(364/172)-1]x100, which was confirmed by a measured 72% increase in ERK1/2 phosphorylation. Ang II type 1 receptor blockade by candesartan (10 micromol/L) abolished the Ang II-induced increase in ERK1/2 activity, but Ang II type 2 receptor blockade (PD123319, 10 micromol/L) did not. The Ang II-induced increase in ERK1/2 activity was inhibited by protein kinase C inhibitors Ro-31-8220 (1 micromol/L) and Go-6976 (300 nmol/L) and tyrosine kinase inhibitors genistein (1 micromol/L, general) and herbimycin A (1 micromol/L, c-Src family). The present findings show for the first time in intact resistance arteries that ERK1/2 activation is rapidly regulated by Ang II, is synergistic with pressure, and is involved in contraction. The ERK1/2 signaling pathway apparently includes upstream protein kinase C and c-Src.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040245     DOI: 10.1161/01.hyp.36.4.617

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

2.  Involvement of RhoA/Rho kinase pathway in myogenic tone in the rabbit facial vein.

Authors:  Caroline Dubroca; Dong You; Bernard I Lévy; Laurent Loufrani; Daniel Henrion
Journal:  Hypertension       Date:  2005-04-18       Impact factor: 10.190

3.  TMEM16A regulates portal vein smooth muscle cell proliferation in portal hypertension.

Authors:  Xi Zeng; Ping Huang; Mingkai Chen; Shiqian Liu; Nannan Wu; Fang Wang; Jing Zhang
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.447

Review 4.  Small artery remodeling in hypertension.

Authors:  Michael J Mulvany
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

5.  Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries.

Authors:  R S Garcha; P S Sever; A D Hughes
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  Smooth muscle 22α facilitates angiotensin II-induced signaling and vascular contraction.

Authors:  Xiao-Li Xie; Xi Nie; Jun Wu; Fan Zhang; Li-Li Zhao; Yan-Ling Lin; Ya-Juan Yin; Hui Liu; Ya-Nan Shu; Sui-Bing Miao; Huan Li; Peng Chen; Mei Han
Journal:  J Mol Med (Berl)       Date:  2014-12-17       Impact factor: 4.599

7.  Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose.

Authors:  Souad Belmadani; Mourad Zerfaoui; Hamid A Boulares; Desiree I Palen; Khalid Matrougui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

8.  Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice.

Authors:  Jun Su; Pamela A Lucchesi; Romer A Gonzalez-Villalobos; Desiree I Palen; Bashir M Rezk; Yasuhiro Suzuki; Hamid A Boulares; Khalid Matrougui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-15       Impact factor: 8.311

9.  Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice.

Authors:  Souad Belmadani; Desiree I Palen; Romer A Gonzalez-Villalobos; Hamid A Boulares; Khalid Matrougui
Journal:  Diabetes       Date:  2008-03-04       Impact factor: 9.461

10.  Protective effects of aspirin from cardiac hypertrophy and oxidative stress in cardiomyopathic hamsters.

Authors:  Rong Wu; David Yin; Nataliya Sadekova; Christian F Deschepper; Jacques de Champlain; Helene Girouard
Journal:  Oxid Med Cell Longev       Date:  2012-07-04       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.